UKMFA Analysis of BioNTech's Securities and Exchange Commission (SEC) Filing Document - March 2022


UKMFA have read and produced this summary of Form 20-F, submitted by BioNTech to the Securities and Exchange Commission (SEC). Form 20-F is the primary disclosure document required from foreign private issuers listing equity shares on exchanges in the United States and requires comprehensive disclosure about the company, including information about risks related to its business operations which could expose the company to liability, and potentially to huge lawsuits and class actions.

BioNTech’s 20-F SEC document,submitted on March 30th 2022, reveals extraordinary discrepancies between Pfizer/BioNTech’s public statements about their COVID-19 product and the disclosures in the filing and raises serious questions and concerns regarding the disparities between what the public is being told and what the company is admitting to in this official document.

Subscribe and Stay Informed

Please sign up to receive our Newsletter to be notified of new UKMFA Campaigns, Open Letters, Calls-to-Action and important updates.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

We will not use your contact details for anything else or supply to any third parties. You can unsubscribe at any time by clicking the link in the footer of our emails.